Putnam Investments LLC boosted its position in shares of Emergent Biosolutions Inc (NYSE:EBS) by 38.7% during the second quarter, HoldingsChannel reports. The institutional investor owned 57,203 shares of the biopharmaceutical company’s stock after purchasing an additional 15,949 shares during the period. Putnam Investments LLC’s holdings in Emergent Biosolutions were worth $2,888,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Stratos Wealth Partners LTD. acquired a new stake in shares of Emergent Biosolutions in the 1st quarter valued at approximately $134,000. PNC Financial Services Group Inc. boosted its stake in shares of Emergent Biosolutions by 108.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 1,482 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Emergent Biosolutions in the 1st quarter valued at approximately $171,000. Financial Gravity Wealth Inc. acquired a new stake in shares of Emergent Biosolutions in the 1st quarter valued at approximately $190,000. Finally, Sei Investments Co. boosted its stake in shares of Emergent Biosolutions by 5,992.1% in the 1st quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 3,775 shares in the last quarter. Hedge funds and other institutional investors own 83.00% of the company’s stock.

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald set a $68.00 price target on shares of Emergent Biosolutions and gave the company a “buy” rating in a research note on Tuesday, September 11th. Argus raised their price target on shares of Emergent Biosolutions to $70.00 and gave the company an “average” rating in a research note on Tuesday, September 11th. They noted that the move was a valuation call. Chardan Capital raised their price target on shares of Emergent Biosolutions from $60.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, September 4th. Cowen restated a “hold” rating and issued a $49.00 price target on shares of Emergent Biosolutions in a research note on Wednesday, August 29th. Finally, Wells Fargo & Co set a $65.00 price target on shares of Emergent Biosolutions and gave the company a “hold” rating in a research note on Wednesday, August 29th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $61.63.

In related news, CEO Daniel Abdun-Nabi sold 90,776 shares of the firm’s stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $60.18, for a total value of $5,462,899.68. Following the completion of the transaction, the chief executive officer now owns 257,343 shares in the company, valued at approximately $15,486,901.74. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Ronald Richard sold 7,893 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $60.02, for a total transaction of $473,737.86. Following the completion of the transaction, the director now owns 21,063 shares of the company’s stock, valued at approximately $1,264,201.26. The disclosure for this sale can be found here. In the last quarter, insiders sold 194,626 shares of company stock valued at $11,517,404. 13.40% of the stock is owned by company insiders.

Shares of NYSE EBS opened at $66.51 on Wednesday. The company has a market capitalization of $3.32 billion, a P/E ratio of 35.01, a price-to-earnings-growth ratio of 1.42 and a beta of 1.25. Emergent Biosolutions Inc has a 1 year low of $36.38 and a 1 year high of $67.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.59 and a quick ratio of 4.15.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.19. The business had revenue of $220.20 million during the quarter, compared to analyst estimates of $208.94 million. Emergent Biosolutions had a net margin of 16.55% and a return on equity of 15.09%. The firm’s quarterly revenue was up 118.5% on a year-over-year basis. During the same quarter last year, the business earned $0.13 EPS. analysts forecast that Emergent Biosolutions Inc will post 2.35 earnings per share for the current fiscal year.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Read More: Do Tariffs Work?

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.